Concepedia

Author

Anne Escande

Institut Gustave Roussy

Also Known As

A. Escande, Anna Pigui, Anne Escande

12

Publications

856

Citations

6

H-Index

22

Concepts

All Affiliations

Institut Gustave RoussyCentre Léon BérardAssistance Publique – Hôpitaux de ParisCentre Hospitalier privé Saint GrégoireHôpital Européen Georges-Pompidou
AE

About

Anne Escande is an author at Institut Gustave Roussy specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

817

2

Health Sciences

2

2

45

3

Pathology

2

2

56

4

Pharmacology

2

2

747

5

Gastroenterology

1

1

39

Anne Escande

×

6

Publications

842

Citations

6

H-Index

YearCitations

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles,

The Lancet

2022

716

Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis

Capucine Baldini, Anne Escande, Olivier Bouché,

Pancreatology

2016

39

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating <i>ESR1</i> mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Thomas Bachelot,

Cancer Research

2022

31

Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment

Philippe Barthélémy, Constance Thibault, Aude Fléchon,

European Urology Oncology

2024

25

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz,

European Journal of Cancer

2020

17

Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).

Philippe Barthélémy, Yohann Loriot, Éric Voog,

Journal of Clinical Oncology

2023

14

Page 1